



XTL BIOPHARMACEUTICALS, LTD. ANNOUNCES MANAGERIAL CHANGE

New York, NY, July 6, 2006 – XTL Biopharmaceuticals, Ltd. (Nasdaq: XTLB, LSE: XTL, TASE: XTL) today announced that as part of the on-going process to consolidate key managerial positions, Mr. Jonathan Burgin, Chief Financial Officer, will depart the Company effective today. Bill Kessler, the Company's Finance Director, will become Principal Financial and Accounting Officer for financial and compliance reporting purposes.

Commenting on Mr. Burgin's departure, Ron Bentsur, XTLbio's Chief Executive Officer, said, "Jonathan is a consummate professional and on behalf of the Company, I want to thank him for 7 years of dedicated service to XTLbio. I wish him much success in his future endeavors."

About XTL Biopharmaceuticals, Ltd.

XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. In addition, XTLbio has out-licensed to Cubist Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical study in hepatitis B liver transplant patients. XTLbio is publicly traded on the Nasdaq, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur
Chief Executive Officer
(212) 531-5971
rbentsur@xtlbio.com